SCHEMBL2914563

SCHEMBL2914563

CCCC(N)CN1CCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.39
ERAP2 Q6P179 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
SLC6A4 P31645 2/20 0.39
MAPT P10636 2/20 0.37
ATM Q13315 1/20 0.37
SLC6A3 Q01959 1/20 0.36
ALDH1A1 P00352 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HPGD P15428 1/20 0.32
KDM4E B2RXH2 1/20 0.31
HSD17B10 Q99714 1/20 0.31
DPP4 P27487 2/20 0.30
CHRM2 P08172 1/20 0.30
CYP2D6 P10635 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
CHRM3 P20309 1/20 0.30
DRD3 P35462 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31391687 0.81 KMT2A (0.42) ANPEPERAP2KMT2AMEN1MAPT
SCHEMBL10386726 0.81 SMN1; SMN2 (0.39) ANPEPERAP2CHRM3SIGMAR1
SCHEMBL20354500 0.80 CARM1 (0.37) MAPTALDH1A1L3MBTL1HRH3
SCHEMBL8553536 0.79 MEN1 (0.46) ANPEPERAP2KMT2AMEN1MAPT
SCHEMBL28301902 0.79 MEN1 (0.46) ANPEPERAP2KMT2AMEN1MAPT
SCHEMBL23278171 0.78 HRH3 (0.39) ANPEPERAP2MAPTALDH1A1L3MBTL1
SCHEMBL1674470 0.78 MEN1 (0.55) ANPEPERAP2KMT2AMEN1MAPT
SCHEMBL7504013 0.75 HRH3 (0.46) MAPTALDH1A1L3MBTL1HRH3
SCHEMBL22564675 0.74 KMT2A (0.46) ANPEPERAP2KMT2AMEN1SLC6A4
SCHEMBL20663279 0.74 KMT2A (0.46) ANPEPERAP2KMT2AMEN1SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286112-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-11-11 US claimed
EP-2200609-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2010-06-30 EP claimed
WO-2009034388-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2009-03-19 WO claimed
US-20100286112-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-11-11 US disclosed
EP-2200609-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2010-06-30 EP disclosed
WO-2009034388-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286112-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS GPR119, DPP4, DPP9 ANPEP 690/4885ERAP2 149/4885KMT2A 2366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.